Another study of eight high-risk CLL patients carrying del(17p) and/or TP53 mutations progressing on venetoclax revealed other recurrent aberrations with resistance-conferring potential and described a rather heterogeneous clonal evolution in venetoclax-treated CLL [19]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.